학술논문
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Document Type
Article
Author
Garcia-Manero, Guillermo; McCloskey, James; Griffiths, Elizabeth A; Yee, Karen W L; Zeidan, Amer M; Al-Kali, Aref; Deeg, H Joachim; Patel, Prapti A; Sabloff, Mitchell; Keating, Mary-Margaret; Zhu, Nancy; Gabrail, Nashat Y; Fazal, Salman; Maly, Joseph; Odenike, Olatoyosi; Kantarjian, Hagop; DeZern, Amy E; O’Connell, Casey L; Roboz, Gail J; Busque, Lambert; Buckstein, Rena; Amin, Harshad; Randhawa, Jasleen; Leber, Brian; Shastri, Aditi; Dao, Kim-Hien; Oganesian, Aram; Hao, Yong; Keer, Harold N; Azab, Mohammad; Savona, Michael R
Source
In The Lancet Haematology January 2024 11(1):e15-e26
Subject
Language
ISSN
2352-3026